New drug zorevunersen offers hope for children with Dravet syndrome

A new drug, zorevunersen, shows significant promise in treating Dravet syndrome, a severe form of epilepsy in children. The drug targets the genetic cause of the condition, managing underlying brain gene defects and drastically reducing seizures in young patients. Early trial results indicate a potential for near-normal lives for affected children, though further research is needed for widespread recommendation.